Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Kimmie Ng; Jeffrey A. Meyerhardt; Andrew T. Chan; Kaori Sato; Jennifer A. Chan; Donna Niedzwiecki; Leonard B. Saltz; Robert J. Mayer; Al B. Benson; Paul L. Schaefer; Renaud Whittom; Alexander Hantel; Richard M. Goldberg; Alan P. Venook; Shuji Ogino; Edward L. Giovannucci; Charles S. Fuchs

doi:10.1093/jnci/dju345

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Kimmie Ng, Jeffrey A. Meyerhardt, Andrew T. Chan, Kaori Sato, Jennifer A. Chan, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Alan P. Venook, Shuji Ogino, Edward L. Giovannucci, Charles S. Fuchs

Research output: Contribution to journal › Article › peer-review

125 Scopus citations

Abstract

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

Original language	English
Journal	Journal of the National Cancer Institute
Volume	107
Issue number	1
DOIs	https://doi.org/10.1093/jnci/dju345
State	Published - 1 Jan 2015
Externally published	Yes

Access to Document

10.1093/jnci/dju345

Cite this

Ng, K., Meyerhardt, J. A., Chan, A. T., Sato, K., Chan, J. A., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Benson, A. B., Schaefer, P. L., Whittom, R., Hantel, A., Goldberg, R. M., Venook, A. P., Ogino, S., Giovannucci, E. L., & Fuchs, C. S. (2015). Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. Journal of the National Cancer Institute, 107(1). https://doi.org/10.1093/jnci/dju345

@article{f8430ab29bd74caca558b66821babd6e,

title = "Aspirin and COX-2 inhibitor use in patients with stage III colon cancer",

abstract = "We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.",

author = "Kimmie Ng and Meyerhardt, {Jeffrey A.} and Chan, {Andrew T.} and Kaori Sato and Chan, {Jennifer A.} and Donna Niedzwiecki and Saltz, {Leonard B.} and Mayer, {Robert J.} and Benson, {Al B.} and Schaefer, {Paul L.} and Renaud Whittom and Alexander Hantel and Goldberg, {Richard M.} and Venook, {Alan P.} and Shuji Ogino and Giovannucci, {Edward L.} and Fuchs, {Charles S.}",

note = "Publisher Copyright: {\textcopyright} The Author 2014. Published by Oxford University Press.",

year = "2015",

month = jan,

day = "1",

doi = "10.1093/jnci/dju345",

language = "English",

volume = "107",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "1",

}

Ng, K, Meyerhardt, JA, Chan, AT, Sato, K, Chan, JA, Niedzwiecki, D, Saltz, LB, Mayer, RJ, Benson, AB, Schaefer, PL, Whittom, R, Hantel, A, Goldberg, RM, Venook, AP, Ogino, S, Giovannucci, EL & Fuchs, CS 2015, 'Aspirin and COX-2 inhibitor use in patients with stage III colon cancer', Journal of the National Cancer Institute, vol. 107, no. 1. https://doi.org/10.1093/jnci/dju345

TY - JOUR

T1 - Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

AU - Ng, Kimmie

AU - Meyerhardt, Jeffrey A.

AU - Chan, Andrew T.

AU - Sato, Kaori

AU - Chan, Jennifer A.

AU - Niedzwiecki, Donna

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Benson, Al B.

AU - Schaefer, Paul L.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Goldberg, Richard M.

AU - Venook, Alan P.

AU - Ogino, Shuji

AU - Giovannucci, Edward L.

AU - Fuchs, Charles S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

AB - We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84926518325&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju345

DO - 10.1093/jnci/dju345

M3 - Article

C2 - 25432409

AN - SCOPUS:84926518325

SN - 0027-8874

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 1

ER -

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Abstract

Access to Document

Fingerprint

Cite this